(Q42279135)

19 October 2017

1 reference

title

Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection (English)

1 reference

19 October 2017

1 reference

1

1 reference

PMC publication ID

2792872

19 October 2017

language of work or name

English

0 references

publication date

29 November 2009

1 reference

Patient Preference and Adherence

19 October 2017

1 reference

19 October 2017

3

1 reference

19 October 2017

345-355

1 reference

Creative Commons Attribution-NonCommercial 3.0 Unported

19 October 2017

start time

1 November 2009

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Paliperidone palmitate - review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792872

Olanzapine dosing above the licensed range is more efficacious than lower doses: fact or fiction?

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792872

Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792872

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792872

A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792872

Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second-generation antipsychotic

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792872

Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792872

Compelling or irrelevant? Using number needed to treat can help decide

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792872

Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792872

Understanding and addressing adherence issues in schizophrenia: from theory to practice.

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792872

How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792872

The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792872

Antipsychotic medication adherence in schizophrenia

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792872

Long-acting injectable risperidone for the treatment of schizophrenia: clinical perspectives

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792872

Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review.

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792872

Defining and assessing adherence to oral antipsychotics: a review of the literature

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792872

Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792872

Cognitive behavior therapy for schizophrenia

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792872

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792872

Insight into schizophrenia: the effects of cognitive behavioural therapy on the components of insight and association with sociodemographics--data on a previously published randomised controlled trial

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792872

Intramuscular olanzapine: a review of its use in the management of acute agitation

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792872

Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792872

Long-acting risperidone: a review of its use in schizophrenia

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792872

Interventions to improve antipsychotic medication adherence: review of recent literature

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792872

A meta-analysis of the efficacy of second-generation antipsychotics

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792872

Predictors of noncompliance in patients with schizophrenia.

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792872

Engagement of patients with psychosis in the consultation: conversation analytic study

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792872

Antipsychotic medication adherence: is there a difference between typical and atypical agents?

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792872

Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792872

The role of depot neuroleptics in the treatment of schizophrenic patients

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792872

Olanzapine pamoate - blockbuster or damp squib?

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792872

Are depot antipsychotics more coercive than tablets? The patient's perspective.

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792872

Psychiatric nurses' attitudes to antipsychotic depots in Hong Kong and comparison with London.

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792872

An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia.

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792872

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792872

A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia.

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792872

Who responds to aripiprazole in clinical practice? An observational study of combination versus monotherapy

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792872

Antipsychotic depot medication and attitudes of community psychiatric nurses.

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792872

Increased suicide attempt rate among patients interrupting use of atypical antipsychotics

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792872

Medication compliance and comorbid substance abuse in schizophrenia: impact on community survival 4 years after a relapse.

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792872

Olanzapine: review of safety 2008

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792872

Predictors of noncompliance in males with first-episode schizophrenia, schizophreniform and schizoaffective disorder

1 December 2018

1 reference

12 December 2020

Attitudes of psychiatrists toward antipsychotic depot medication

1 reference

12 December 2020

Medication supervision and adherence of persons with psychotic disorders in residential treatment settings: a pilot study

1 reference

12 December 2020

Patient satisfaction with, and acceptability of, atypical antipsychotics

1 reference

12 December 2020

Relationships among subjective and objective measures of adherence to oral antipsychotic medications

1 reference

12 December 2020

Postdischarge medication compliance of inpatients converted from an oral to a depot neuroleptic regimen

1 reference

12 December 2020

Association of acute symptoms and compliance attitude in noncompliant patients with schizophrenia

1 reference

12 December 2020

Subjective experience of treatment, side-effects, mental state and quality of life in chronic schizophrenic out-patients treated with depot neuroleptics

1 reference

12 December 2020

The attitude of patients towards antipsychotic depot treatment

1 reference

12 December 2020

Psychiatrists' attitudes to maintenance medication for patients with schizophrenia

1 reference

12 December 2020

Why did John Nash stop his medication?

1 reference

12 December 2020

Predicting medication noncompliance after hospital discharge among patients with schizophrenia

1 reference

12 December 2020

Depot and oral antipsychotics: patient preferences and attitudes are not the same thing

1 reference

12 December 2020

Evidence-based psychosocial treatment for schizophrenia

1 reference

12 December 2020

Insight into illness and adherence to psychotropic medications are separately associated with violence severity in a forensic sample

1 reference

12 December 2020

The role of the therapeutic alliance in the treatment of schizophrenia. Relationship to course and outcome

1 reference

12 December 2020

Identifiers

DOI

10.2147/PPA.S5734

1 reference

19 October 2017

1 reference

PMC publication ID

2792872

19 October 2017

PubMed publication ID

20016798

1 reference

PMC publication ID

2792872